| Biomarker ID | 970 |
| PMID | 22887127 |
| Year | 2012 |
| Biomarker | miR-375; miR-141; miR-378*; |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Primary Tumors: [miR-375 and miR-141]; Downregulated in Primary Tumors: [miR-378*] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(miRNA- 375):-DNA-binding transcription factor activity, RNA polymerase II-specific; DNA-binding transcription factor activity; nuclear chromatin; chromatin; nuclear chromosome Pathways Include(miRNA-141):- regulation of RNA metabolic process; Gene expression (Transcription); RNA Polymerase II Transcription; nuclear chromosome; DNA-binding transcription factor activity, RNA polymerase II-specific Pathways Include(miR-378):- anatomical structure morphogenesis; synapse; DNA binding; negative regulation of gene expression; cell morphogenesis |
| Experiment | Normal Vs Primary Tumor |
| Type of Biomarker | Prognostic |
| Cohort | 28 patients with Localized low risk, 30 with Localized high risk, and 26 with Metastatic Castration Resistant Prostate Cancer were selected for the study. 28 normal prostate tissue, 99 primary tumor, and 14 meta- stases samples were selected for validation |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.0001 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent dataset |
| Technical Name | miR-375, miR-141, miR-378* |